7. Patients can be considered to enter the trial if they meet any one of the following criteria: 1) They are naive to pasireotide 2) They have received pasireotide in the past and have been discontinued because of lack of efficacy (2 weeks for washout prior to screening for patients treated with pasireotide subcutaneously and 12 weeks of washout prior to screening for patients treated with pasireotide LAR) 3) Patients who are on maximal tolerated dose but have not achieved biochemical control